| Species |
Canine |
| Protein Construction |
BMPR1A/ALK-3 (Gln24-Arg152)
Accession # NP_001138622.1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to inhibit rhBMP4induced alkaline phosphatase production by ATDC5 cells. The ED50 for this effect is typically 0.5 2.5 μg/mL in the presence of 50 ng/mL of recombinant human BMP4. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
40.94 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The type IA bone morphogenetic protein receptor (Bmpr1a), encoded by 11 exons and spanning about 40 kb on chromosome 14 in mice and chromosome 10 in human (Derynck & Feng, 1997; Mishina, Hanks, Miura, Tallquist, & Behringer, 2002), is an essential receptor for BMP signaling. |
| Synonyms |
BMPR1A; ALK-3; ALK3; ALK 3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
